Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Galena Biopharma: The Oncologist's Perspective On A Life Saving Therapy
Seeking Alpha
Thursday, February 20, 2014 - 8:12am
tags:
Galena Biopharma, NeuVax, Dendreon, Provenge, prostate cancer, vaccines, breast cancer
Roche May Share Trial Data on Avastin Amid Brain Cancer Conflict
Bloomberg
Thursday, February 20, 2014 - 8:09am
tags:
Roche, Avastin, glioblastoma
Bayer, Novartis, others eye Merck's consumer health unit - sources
Yahoo/Reuters
Thursday, February 20, 2014 - 8:08am
tags:
Merck, consumer health, M&A, Bayer, Novartis, Reckitt Benckiser, Procter & Gamble
Novo Nordisk targets Mexico for early obesity drug launch
Fierce Pharma
Wednesday, February 19, 2014 - 12:57pm
tags:
Novo Nordisk, obesity, Mexico, liraglutide
3 Small Cap Biotechs Developing Novel Cancer Treatments
Motley Fool
Wednesday, February 19, 2014 - 12:56pm
tags:
Inovio, VGX-3100, Cervical Intraepithelial Neoplasia, MM-398, Merrimack Pharmaceuticals, acute myeloid leukemia, vosaroxin, Sunesis
Arrowhead: A Functional Cure For The Hepatitis B Virus
Seeking Alpha
Wednesday, February 19, 2014 - 12:49pm
tags:
Arrowhead Research, hepatitis B, RNAi
Furiex Said to Seek Buyer as Experimental Drug Meets Targets
Bloomberg
Wednesday, February 19, 2014 - 12:48pm
tags:
Furiex Pharmaceuticals, eluxadoline, M&A, irritable bowel syndrome
Athersys: Two Crucial Near-Term Events
Seeking Alpha
Wednesday, February 19, 2014 - 12:47pm
tags:
Athersys, MultiStem, stem cells, Osiris, RTI Surgical
Actavis-Forest Bid Shines Light on Valeant Next: Real M&A
Bloomberg
Wednesday, February 19, 2014 - 11:18am
tags:
Actavis, Forest Labs, M&A, Valeant Pharmaceuticals, Mylan, Teva Pharmaceuticals
Report: Medtech tax has cost 33,000 jobs already
Mass Device
Wednesday, February 19, 2014 - 10:20am
tags:
devices, medical device tax, layoffs
Rise of Alnylam, ISIS Gives RNA Therapeutics Value
Wall St Cheat Sheet
Wednesday, February 19, 2014 - 10:17am
tags:
Alnylam, Isis Pharmaceuticals, RNAi
Glaxo Memo Shows Drug Industry Lobbying on E-Cigarettes
Bloomberg
Wednesday, February 19, 2014 - 9:55am
tags:
GSK, smoking cessation, e-cigarettes
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug
Yahoo/Zacks.com
Wednesday, February 19, 2014 - 9:26am
tags:
Regeneron, Eylea, Gilead Sciences, ledipasvir, Sovaldi, hepatitis C, Cangrelor, The Medicines Company
Should FDA and EMA Team up to Approve Drugs on a Reciprocal Basis?
Regulatory Focus
Wednesday, February 19, 2014 - 8:57am
tags:
FDA, drug approvals, Europe, EMA
Tokyo prosecutors raid Novartis Japan offices in probe
Reuters
Wednesday, February 19, 2014 - 8:46am
tags:
Japan, Diovan, Novartis
The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind
Motley Fool
Wednesday, February 19, 2014 - 8:44am
tags:
Myriad Genetics, Questcor, Ziopharm, Sarepta Therapeutics, MannKind
Can a New Indication for Lyrica Help Results at Pfizer?
Motley Fool
Wednesday, February 19, 2014 - 8:42am
tags:
Lyrica, Pfizer, restless legs syndrome
Eli Lilly's Ramucirumab for lung cancer meets Phase III survival endpoint
Yahoo/Fly on the Wall
Wednesday, February 19, 2014 - 8:41am
tags:
Eli Lilly, ramucirumab, non-small cell lung cancer
Teva decides not to proceed to randomization stage of trial for laquinimod
Yahoo/Fly on the Wall
Wednesday, February 19, 2014 - 8:40am
tags:
laquinimod, clinical trials, Teva Pharmaceuticals, Relapsing Remitting Multiple Sclerosis, RRMS, MS, Active Biotech
Boehringer blood thinner lawsuits due to start in August
Yahoo/Reuters
Wednesday, February 19, 2014 - 8:39am
tags:
Boehringer Ingelheim, bloodthinners, Pradaxa

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.